Fred Alger Management, LLC Bei Gene, Ltd. Transaction History

Fred Alger Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $1.01 Million - $1.64 Million	-4,057 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$292.75 - $367.01 $50,938 - $63,859	-174 Reduced 4.11%	4,057 $1.39 Million
Q1 2021 May 17, 2021	SELL	$260.64 - $382.12 $16,159 - $23,691	-62 Reduced 1.44%	4,231 $1.47 Million
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $21,467 - $30,711	-97 Reduced 2.21%	4,293 $1.11 Million
Q3 2020 Nov 13, 2020	BUY	$189.18 - $286.44 $262,960 - $398,151	1,390 Added 46.33%	4,390 $1.26 Million
Q2 2020 Aug 14, 2020	BUY	$123.9 - $195.41 $371,700 - $586,230	3,000 New	3,000 $565,000
Q2 2019 Aug 14, 2019	SELL	$113.99 - $146.86 $683,940 - $881,160	-6,000 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$122.82 - $151.83 $736,920 - $910,980	6,000 New	6,000 $792,000
Q4 2018 Feb 14, 2019	SELL	$107.01 - $175.15 $2.23 Million - $3.64 Million	-20,799 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$152.62 - $189.66 $429,014 - $533,134	2,811 Added 15.63%	20,799 $3.58 Million
Q2 2018 Jul 19, 2018	BUY	$152.5 - $216.77 $414,495 - $589,180	2,718 Added 17.8%	17,988 $2.77 Million
Q1 2018 May 10, 2018	BUY	$97.41 - $177.22 $1.49 Million - $2.71 Million	15,270 New	15,270 $2.57 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.